ETRA
Electra Therapeutics, Inc.
Healthcare — Biotechnology
Electra Therapeutics, Inc. is a clinical-stage biotechnology company. It develops therapies that target signal regulatory proteins for the treatment of novel targets for diseases in immunology and cancer. Its product, ELA026, is a monoclonal antibody that targets signal regulatory protein on the cell surface of myeloid and T cells and depletes pathological immune cells, enabling medical professionals to find an approved treatment for secondary hemophagocytic lymphohistiocytosis, a life-threatening hyperinflammatory condition. The company was incorporated in 2018 and is based in South San Francisco, California.
Price History
Fundamentals
| Market Cap | $850.82M |
| P/E Ratio (TTM) | - |
| Forward P/E | - |
| EPS (TTM) | $-2.61 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | - |
| Debt/Equity | 2.16 |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | - |
| Beta | - |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $15.50 |
| 52-Week Low | $13.11 |
| 50-Day Avg | $13.63 |
| 200-Day Avg | $13.63 |
| Avg Volume | $2.13M |
| Volume | 145.0K |
Performance Analysis
NEUTRALETRA presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Sep 23, 2026 15:03 UTC
Back to Screener Export Report